John Aston
Geen lopende functies
Vermogen: 77 132 $ op 30-04-2024
Profiel
John C.
Aston served as Chairman of International Biotechnology Trust Plc from 2017 to 2019.
He was an Independent Non-Executive Director of Polar Capital Global Healthcare Trust Plc from 2010 to 2018.
He also held positions as Director-Investment Banking at Schroders Plc, Director at Convergence Pharmaceuticals Ltd., Director at Calchan Holdings Ltd., and Director at Calchan Ltd.
Prior to these roles, he was the Chief Financial Officer of MedImmune Ltd.
from 1996 to 2006 and Chief Financial Officer of Astex Therapeutics Ltd.
from 2007 to 2010.
He was also a Principal at BTG Ltd.
Mr. Aston received his undergraduate degree from the University of Cambridge.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-02-2024 | 10 000 ( 0.03% ) | 77 132 $ | 30-04-2024 |
Eerdere bekende functies van John Aston
| Bedrijven | Functie | Einde |
|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | Voorzitter | 11-12-2019 |
| POLAR CAPITAL GLOBAL HEALTHCARE TRUST PLC | Directeur/Bestuurslid | 28-02-2018 |
Astex Therapeutics Ltd.
 Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Financieel Directeur/CFO | 01-05-2010 |
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Financieel Directeur/CFO | 30-06-2006 |
Calchan Holdings Ltd.
 Calchan Holdings Ltd. Pharmaceuticals: MajorHealth Technology Calchan Holdings Ltd. develops novel oral state-dependent calcium channel modulators for chronic pain. The company was founded on February 25, 2011 and is headquartered in London, the United Kingdom. | Directeur/Bestuurslid | - |
Opleiding van John Aston
| University of Cambridge | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SCHRODERS PLC | Finance |
| Bedrijven in privébezit | 10 |
|---|---|
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Astex Therapeutics Ltd.
Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
BTG Ltd.
 BTG Ltd. Pharmaceuticals: MajorHealth Technology BTG Ltd. is a global healthcare company, which focuses on interventional medicine that can help physicians to treat patients through minimally invasive procedures. It operates through the following segments: Product, Licensing, and Other. The firm's products include CroFab, DigiFab, Voraxage. The company was founded on December 12, 1991 and is headquartered in Farnham, the United Kingdom. | Health Technology |
Regenerative Medicine Assets Ltd.
 Regenerative Medicine Assets Ltd. Pharmaceuticals: MajorHealth Technology Regenerative Medicine Assets Ltd. engaged in the healthcare business. The company was founded by Paul Kemp in 2000 and was headquartered in Bristol, the United Kingdom. | Health Technology |
International Biotechnology Trust Plc
 International Biotechnology Trust Plc Investment Trusts/Mutual FundsMiscellaneous International Biotechnology Trust Plc is a closed end investment trust company, which invests in the development staged biotechnology and other life sciences industries. The company was founded on January 1, 1994 and is headquartered in London, the United Kingdom. | Miscellaneous |
Polar Capital Global Healthcare Trust Plc
 Polar Capital Global Healthcare Trust Plc Investment Trusts/Mutual FundsMiscellaneous Polar Capital Global Healthcare Trust Plc is an investment company. Its portfolio includes healthcare stocks across all four healthcare sub-sectors. The company was founded on May 12, 2010 and is headquartered in London, the United Kingdom. | Miscellaneous |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| Steering Group | |
Calchan Ltd.
 Calchan Ltd. BiotechnologyHealth Technology Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
Calchan Holdings Ltd.
Calchan Holdings Ltd. Pharmaceuticals: MajorHealth Technology Calchan Holdings Ltd. develops novel oral state-dependent calcium channel modulators for chronic pain. The company was founded on February 25, 2011 and is headquartered in London, the United Kingdom. | Health Technology |